BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab...
...advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma patients who have received a prior trastuzumab-based...
BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

...data showing zanidatamab led to a confirmed objective response rate (ORR) of 47% in 15 Herceptin trastuzumab-naïve...
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

...have improved progression-free survival (PFS) versus Herceptin trastuzumab...
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...or high-flow oxygen or other non-invasive ventilation at the start of treatment. The committee also backed Enhertu trastuzumab...
...ligand 1TNF – Tumor necrosis factorTROP2 (TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Sandi Wong Veklury, remdesivir (GS-5734) Enhertu, fam-trastuzumab...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...the partners’ previous success with anti-HER2 ADC Enhertu fam-trastuzumab...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...Nerlynx neratinib as extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer, following adjuvant trastuzumab-based...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...stimulates myeloid cell activity, such as Herceptin trastuzumab...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...stimulates myeloid cell activity, such as Herceptin trastuzumab...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...the pharma’s winning bet on the ADC Enhertu fam-trastuzumab...
...of targeted breast cancer drugs, including Herceptin trastuzumab...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...of Avastin bevacizumab, Rituxan/MabThera rituximab and Herceptin trastuzumab...
Items per page:
1 - 10 of 1289